Life science company that develops reagents for biomarker & drug discovery scientists through 3 brands ELISA Genie, Assay Genie & Antibody Genie. The company was founded in 2017 by two former Post-Doctoral researchers Colm Ryan (CEO) and Seán Mac Fhearraigh (CTO).
ELISA Genie has over 26,000 ready-to-use ELISA kits as well as offering the companies GeniePlex Multiplex Immunoassay technology. Genieplex kits allow researchers to multiplex up to 24 analytes using only 15μL by flow cytometry. GeniePlex multiplex assay technology utilizes multiple bead populations differentiated by size and different levels of fluorescence intensity to allow simultaneous measurement of analytes.
Assay Genie offers 1,200 assays, kits, cellular probes and tracking dyes.
The RT-qPCR test is an efficient method for detecting SARS-CoV-2, it measures levels of nucleic acid in a variety of respiratory samples in vitro. The Assay Genie Coronavirus COVID-19 (Strain 2019-nCoV) One-Step RT-qPCR Detection Kit allows efficient cDNA synthesis and Real-Time PCR in a single tube. It also contains one set of primers and fluorescent probes to differentiate between 2019-nCoV and SARS-CoV (or bat SARS related CoV).
Assay Genie also provides ACE2 assay kits that detect COVID-19 activity. The Assay Genie ACE2 activity assay kit measures ACE2 activity by utilizing the ability of an active ACE2 to cleave a synthetic MCA based peptide substrate to release a free fluorophore. The released MCA can be easily quantified using a fluorescence microplate reader.
Antibody Genie supplies over 15,000 cell biology and flow cytometry antibodies.
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.